Recombinant zoster vaccine (RZV/Shingrix) two-dose series for adults 50 or older. First dose at age 50, second dose 2-6 months later. Over 90% efficacy against herpes zoster. Also recommended for immunocompromised adults 19 or older.
Use the full interactive calculator below, or